Results 141 to 150 of about 314,849 (336)

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Maternal Immune Thrombocytopenic Purpura Leading to Severe Neonatal Autoimmune Thrombocytopenia: Report of Two Cases

National Board of Examinations Journal of Medical Sciences
Introduction: In neonatal intensive care units, neonatal thrombocytopenia is one of the common hematological abnormality seen. Neonatal autoimmune thrombocytopenia should be considered in any neonate who is born to a known case of immune thrombocytopenia
Khushwant Kaur, Varughese PV, Nidhie Shajan   +2 more
doaj   +1 more source

Influence of Spleen on Thrombocytopenia Induced by Humoral Factor(s) of Experimental Hypersplenism [PDF]

, 1961
Ruy Pérez-Tamayo, Silvana Londoño Mejía, I Montfort   +2 more
openalex   +1 more source

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR‐Mutated Advanced NSCLC

Clinical Pharmacology &Therapeutics, EarlyView.
Osimertinib, a third‐generation, central nervous system‐active epidermal growth factor receptor‐tyrosine kinase inhibitor, potently and selectively inhibits epidermal growth factor receptor‐tyrosine kinase inhibitor sensitizing and T790M resistance mutations, with efficacy in epidermal growth factor receptor‐mutated non‐small cell lung cancer.
Jincheng Yang, Damilola Olabode, Aarti Sawant‐Basak, Richard Baldry, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Diansong Zhou, Azar Shahraz   +10 more
wiley   +1 more source

A study of Naphthionin in the management of the bleeding defect in patients with thrombocytopenia [PDF]

, 1964
L. Poller, James More
openalex   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Trombocitopenia en el embarazo: gestacional, inmune y congénita

Revista Cubana de Hematología, Inmunología y Hemoterapia
La trombocitopenia afecta hasta el 10 % de todos los embarazos y es un diagnóstico común y un problema en el manejo de las pacientes, ya que puede estar relacionado con condiciones prexistentes presentes en las mujeres en edad fértil, como la ...
Yusselys Cabrera Payne, Dunia Castillo González   +1 more
doaj  

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Hepatopulmonary syndrome (HPS) is associated with increased waitlist mortality in liver transplantation (LT) candidates. Children with HPS are granted Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) exception points for waitlist prioritization in the United States based on criterion developed for adults.
Muhammad H. Raza, Yong Kwon, Pierre Kobierski, Asish C. Misra, Angelina Lim, Cameron Goldbeck, Kambiz Etesami, Rohit Kohli, Juliet Emamaullee   +8 more
wiley   +1 more source